Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...

Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ...

(Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics ...

As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...

ONO-2808 is under clinical development by Ono Pharmaceutical and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, ...

Telephone 0081 43 226 2129; fax 0081 43 226 2160; emailsakaki{at}med.m.chiba-u.ac.jp OBJECTIVES Urinary dysfunction and orthostatic hypotension are the prominent autonomic features in multiple system ...